Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1957 1
1958 1
1961 3
1963 1
1967 2
1970 1
1973 1
1977 1
1982 1
1985 1
1987 1
1988 1
1989 1
1990 1
1997 1
1998 1
1999 1
2001 1
2002 3
2004 4
2008 1
2009 3
2010 7
2011 3
2012 3
2013 1
2014 2
2016 1
2017 3
2018 4
2019 2
2020 7
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

66 results
Results by year
Filters applied: . Clear all
Page 1
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.
Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA. Fong L, et al. Among authors: markman b. Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15. Cancer Discov. 2020. PMID: 31732494 Free PMC article. Clinical Trial.
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors.
Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B. Desai J, et al. Among authors: markman b. J Clin Oncol. 2020 Jul 1;38(19):2140-2150. doi: 10.1200/JCO.19.02654. Epub 2020 Mar 17. J Clin Oncol. 2020. PMID: 32182156 Free PMC article. Clinical Trial.
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O, Kee D, Markman B, Michael M, Underhill C, Carlino MS, Jackett L, Lum C, Scott C, Nagrial A, Behren A, So JY, Palmer J, Cebon J. Klein O, et al. Among authors: markman b. Clin Cancer Res. 2020 Sep 1;26(17):4454-4459. doi: 10.1158/1078-0432.CCR-20-0621. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532787
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J, Deva S, Lee JS, Lin CC, Yen CJ, Chao Y, Keam B, Jameson M, Hou MM, Kang YK, Markman B, Lu CH, Rau KM, Lee KH, Horvath L, Friedlander M, Hill A, Sandhu S, Barlow P, Wu CY, Zhang Y, Liang L, Wu J, Paton V, Millward M. Desai J, et al. Among authors: markman b. J Immunother Cancer. 2020 Jun;8(1):e000453. doi: 10.1136/jitc-2019-000453. J Immunother Cancer. 2020. PMID: 32540858 Free PMC article. Clinical Trial.
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Klein O, et al. Among authors: markman b. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814. JAMA Oncol. 2020. PMID: 32729929 Clinical Trial.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M, Meniawy T, Markman B, Mileshkin L, Harnett P, Millward M, Lundy J, Freimund A, Norris C, Mu S, Wu J, Paton V, Gao B. Friedlander M, et al. Among authors: markman b. Lancet Oncol. 2019 Sep;20(9):1306-1315. doi: 10.1016/S1470-2045(19)30396-1. Epub 2019 Aug 1. Lancet Oncol. 2019. PMID: 31378459 Clinical Trial.
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial.
Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ. Jonker DJ, et al. Among authors: markman b. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1. Lancet Gastroenterol Hepatol. 2018. PMID: 29397354 Clinical Trial.
Biomarkers in colorectal cancer.
Markman B, Rodríguez-Freixinos V, Tabernero J. Markman B, et al. Clin Transl Oncol. 2010 Apr;12(4):261-70. doi: 10.1007/s12094-010-0502-z. Clin Transl Oncol. 2010. PMID: 20462835 Review.
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Markman B, Dienstmann R, Tabernero J. Markman B, et al. Oncotarget. 2010 Nov;1(7):530-43. doi: 10.18632/oncotarget.101012. Oncotarget. 2010. PMID: 21317449 Free PMC article. Review.
66 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page